摘要
目的预测2019新型冠状病毒(2019 novel coronavirus,2019-nCoV)刺突蛋白的抗原表位,分析刺突蛋白的变异规律。方法从基因库(GenBank)和全球共享禽流感数据倡议组织数据库下载2019-nCoV的基因序列(截至2020年3月4日)。应用ClustalW、MEGA 7.0、免疫表位数据库等生物信息学软件,预测刺突蛋白潜在的B淋巴细胞和T淋巴细胞表位,分析比较刺突蛋白的变异在表位区与非表位区的特点。统计学分析采用χ^2检验。结果刺突蛋白有130个潜在表位,包括25个线性B淋巴细胞表位、18个非线性B淋巴细胞表位、71个人类白细胞抗原(human leukocyte antigen,HLA)Ⅰ类限制性T淋巴细胞表位和16个HLAⅡ类限制性T淋巴细胞表位。S404-426肽段有较高的抗原性,且在中国的人群覆盖率达73.4%。与1月31日之前的2019-nCoV刺突蛋白相比,其在1月31日之后的变异频率在非表位区(15.4%比21.7%)和表位区(6.2%比8.7%)都有所增加,但差异均无统计学意义(均P>0.05)。结论2019-nCoV刺突蛋白有多个抗原表位,为2019-nCoV疫苗的研究提供了参考依据。刺突蛋白的变异有增加趋势,需进一步关注和研究。
Objective To predict the epitopes of the spike protein of 2019 novel coronavirus(2019-nCoV)and to analyze the mutation characteristics of this protein.Methods The gene sequences of 2019-nCoV was downloaded from GenBank and Global Initiative on Sharing All Influenza Data database(as of March 4,2020).ClustalW,MEGA 7.0,Immune Epitope Database and other software were used for predicting potential B lymphocyte and T lymphocyte epitopes of spike protein,and then mutations were compared in epitope and non-epitope regions.Statistical analysis was performed with chi-square test.Results There were 130 potential epitopes,including 25 linear B lymphocyte epitopes,18 non-linear B lymphocyte epitopes,71 human leukocyte antigen(HLA)class-Ⅰrestricted T lymphocyte epitopes,and 16 HLA class-Ⅱrestricted T lymphocyte epitopes in spike protein.S404-426displayed the higher antigenicity-score,and its population coverage was 73.4%in China.Compared with the spike protein before January 31,the mutation frequencies of spike protein were increased both in non-epitope(15.4%vs 21.7%)and epitope regions(6.2%vs 8.7%)after January 31,but the differences were not statistically significant(both P>0.05).Conclusions The study identifies several epitopes of 2019-nCoV spike protein,which provides a preliminary basis for the study of 2019-nCoV vaccine.Mutations in spike protein have an increasing trend which needs more attention and research in the future.
作者
李虎
陈志伟
胡鹏
Li Hu;Chen Zhiwei;Hu Peng(Department of Infectious Diseases,Institute for Viral Hepatitis,The Key Laboratory of Molecular Biology for Infectious Diseases,Chinese Ministry of Education,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
出处
《中华传染病杂志》
CAS
CSCD
2020年第11期701-704,共4页
Chinese Journal of Infectious Diseases
基金
重庆医科大学附属第二医院“宽仁英才”项目。